GI side effects from GLP-1 drugs are dose-dependent and vary significantly between compounds, with long-acting agents causing less nausea but more diarrhea than short-acting ones.
p = 0.0009Significance level for metformin increasing vomiting risk when combined with GLP-1 receptor agonists
What the researchers found
GI side effects from GLP-1 receptor agonists are dose-dependent: higher doses cause more nausea (p=0.0017 across all agents) and diarrhea (p=0.031). Adding metformin as background treatment significantly worsened nausea (p=0.04) and vomiting (p=0.0009). Long-acting GLP-1 drugs (like liraglutide, dulaglutide, exenatide weekly) caused less nausea and vomiting than short-acting ones (like exenatide twice daily), but caused more diarrhea. Among long-acting agents, albiglutide and exenatide weekly had less nausea than liraglutide, while dulaglutide was similar to liraglutide.
Why it matters
GI side effects are the number-one reason people stop taking GLP-1 drugs. This systematic analysis gives doctors and patients a clearer picture of which specific drugs cause the most nausea, vomiting, and diarrhea — and shows that dose, background medications, and duration of action all matter. It helps guide prescribing decisions, especially for patients already on metformin or those who are sensitive to nausea.
How the study worked
The researchers searched PubMed for phase 3 clinical trials of GLP-1 receptor agonists and selected 32 trials. They systematically compared the proportion of patients reporting nausea, vomiting, or diarrhea across different drugs, doses, and background medications. They calculated relative risks with 95% confidence intervals, using exenatide twice daily as the reference for short-acting agents and liraglutide as the reference for long-acting agents.
Who was studied
Patients with type 2 diabetes enrolled in 32 phase 3 clinical trials of GLP-1 receptor agonists
What this study cannot tell us
This was a systematic analysis of published trial data, not a meta-analysis of individual patient data. The comparison across trials is limited by differences in study populations, trial design, and reporting methods. Adverse event reporting in clinical trials can undercount real-world side effects. The analysis did not include newer agents like semaglutide or tirzepatide.
How to read the evidence
This is a systematic analysis of 32 phase 3 clinical trials, providing a broad evidence base, though it analyzes published aggregate data rather than individual patient records.
When this study was published
Published in 2017, this study predates the widespread use of semaglutide and tirzepatide. The dose-response and drug-interaction findings remain relevant, but the specific drug comparisons don't include the most commonly prescribed GLP-1 agents today.
The bigger picture
As millions of people start GLP-1 drugs for weight loss and diabetes, GI side effects remain the leading cause of discontinuation. This analysis provides one of the most comprehensive comparisons of GI tolerability across GLP-1 agents, helping clinicians match patients to the drug least likely to cause the side effects they're most concerned about. The finding that metformin amplifies GI problems is especially relevant since many type 2 diabetes patients take both drugs.
Questions still open
- Would newer GLP-1 drugs like semaglutide and tirzepatide follow the same dose-dependent pattern for GI side effects?
- Does the metformin interaction with GLP-1 drugs persist long-term or only during the initial titration period?
- Could slow dose escalation protocols eliminate the tolerability differences between short-acting and long-acting GLP-1 agents?
Common questions
Which GLP-1 drug causes the least nausea?
Does taking metformin with a GLP-1 drug make side effects worse?
Read the original research
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Diabetes, obesity & metabolism, 19(3), 336-347
Citation
Bettge, Karolin; Kahle, Melanie; Abd El Aziz, Mirna S; Meier, Juris J; Nauck, Michael A. (2017). Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.. Diabetes, obesity & metabolism, 19(3), 336-347. https://doi.org/10.1111/dom.12824